• infectious diseases
  • cancer
  • metabolic disorders
  • rare genetic disorders
  • business strategy
  • about us
  • product pipeline
  • science
  • partners
  • patients
  • investors
  • newsroom
  • careers
  • our company
  • our people
  • contact us
  • product pipeline
  • drug candidates
  • LNA drug platform
  • drug discovery engine
  • mechanism of action
  • intellectual property
  • scientific publications
  • partners & collaborators
  • clinical trials & resources
  • investors
  • corporate governance
  • news releases
  • media kit
  • events

   contact us

  • management
  • the board

Santaris Pharma A/S makes medical history and advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat patients infected with Hepatitis C virus

news releases

16 Apr 2013
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines
27 Mar 2013
Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
8 Jan 2013
Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against disease causing microRNAs
7 Jan 2013
USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent licensed to Regulus
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003

Learn more about Santaris Pharma A/S drugs in development

learn more

 
Copyright © 2010, 2011 Santaris Pharma A/S | Terms & Conditions | Privacy Policy | Site Map | Home
DESIGNED BY MENTUS